# Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies

> **NCT01335256** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 10 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BAY1000394

## Key facts

- **NCT ID:** NCT01335256
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2013-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01335256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01335256, "Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01335256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*